When Novartis AG’s irritable bowel syndrome therapy tegaserod (Zelnorm) was found to carry an increased risk of cardiovascular adverse events last spring, drug review and drug safety officials at the Food & Drug Administration engaged in an intense internal debate over how to respond.
After much back-and-forth between officials at the Office of Surveillance & Epidemiology (drug safety) and the Office of New Drugs...





